Lombard Medical Technologies Share Discussion Threads

[nod] 15/4/2010 07:41

well done greynag - you were days ahead of the RNS

[webshares] 12/4/2010 19:32

another coupke of rises of the next week or so and you could almost say we've reached the bottom and have turned a corner...... happy to hold

[greynag] 12/4/2010 14:28

Aorfix
Mark Fillinger, Lebanon, USA, presented an update on the US Pythagoras clinical trial of the Aorfix (Lombard Medical) endograft for abdominal aortic aneurysms.
"The implant has been used at multiple centers to treat highly angulated necks (>60°) and very tortuous anatomy with excellent success rates," he said. "Pilot study results are good, and mirror the European results (RADAR registry).
Unprecedented neck angulation and gender distribution in this trial: this device may expand the number of patients who can be treated with EVAR."

Today's News from CX.

[greynag] 12/4/2010 14:20

Stephen Greenhalgh, BIBA Medical, London, UK, set the scene with a presentation which on the told the story of the remorseless endovascular revolution, based on the research findings of the European Vascular and Endovascular Monitor (EVEM). "We have found that Endovascular procedures continue to grow and the number of surgical procedures is declining.

With regard to abdominal aortic aneurysm, EVAR is a small but growing proportion of AAA procedures in Europe. EVAR penetration is far greater in the Unites States and European Trials appear to have had little effect, said Greenhalgh.

Next-generation of EVAR devices

The session on new EVAR devices was bursting at the seams with participants thronging to learn about the latest updates.

John Hardman, Bath, UK, presented on "Innovation for angulation: The Aorfix stent graft."

"Some of the challenges with high neck angulation are that these result in increased type I endoleaks, increased stent migration and difficulties in retrieving any top caps. The challenges with high iliac angulation are iliac limb kinking and iliac limb occlusions," he said.

Hardman summarised the results of the ARBITER 2 study with, "EVAR for abdominal aortic aneurysm with high angled necks using the Aorfix graft appears to be safe and effective in the short term. The device is now licensed for neck angles up to 90°."

"ARBITER 2 has a small patient number, more data and follow-up are needed, and we await the USA study," he said.

Hardman concluded that the flexible helical ring design and absence of a supra renal fixation conforms to angulated anatomy. "Registry and prospective studies have revealed that Aorfix has good clinical outcomes in angulated anatomy and very low limb occlusion rate," he said.

[johnyee 7] 12/4/2010 13:28

results will be out this friday,maybe thats why their were big buys last week.

[flyfisher09] 12/4/2010 10:30

There seems to have been some hefty trades last week, largest seems to be a buy of 10,000,000 shares worth £97.00K as well as buys(not confirmed)worth £37.05k, £53.01k, £55.95k, £46.50K and £50.00k.

Anyone know what is going on?

[balcony] 17/3/2010 12:08

!0m -Thats a fair trade

[greynag] 05/3/2010 08:37

What is even more encouraging is that Aorfix seems suitable for a greater number of women patients. Consequently, nearly a quarter of Aorfix implants involve females (compared to 6% - 13% involving competitor products).
I'm surprised that Lombard didn't highlight this perhaps unexpected aspect as it expands the Aorfix market.
To emphasize the importance of the gender anomaly, Cook have an on-going trial of a Zenith AAA low profile stent graft with a smaller diameter neck.

[nod] 04/3/2010 20:49

Encouraging to see the patient numbers...

The data presented was from Lombard's Retrospective Aorfix(TM) Data Retrieval
("RADAR") voluntary registry for all Aorfix(TM) customers. Dr Phillips stated
that the Aorfix(TM) device has been utilized in the largest series of patients
with difficult and tortuous anatomy ever studied, yet still had outstanding
clinical results, highlighted by a very low incidence of stent migration (0%),
wire fracture (0.25%) and graft limb occlusion (0.25%) at 12 months in the
data set of 461 eligible patients

In the session attended by many of the leading vascular interventionalists in
the country, Dr Phillips also gave a brief update on recruitment into Lombard's
pivotal FDA study for Aorfix(TM) in which he stated that, to date, more than 175
patients had been recruited into the trial, and that the Company requires 160
patients with follow-up to 12 months for submission to the FDA (minimum 40 low
angle and 120 high angle). The Company has now recruited patients in excess of
the minima and is on track to have the required number of patients with
appropriate follow-up completed during the first half of 2011.

[webshares] 04/3/2010 11:56

I agree, as soon as more confidence into the likelyhood of the product being viable the share price will rocket no doubt about it.... a few more hurdles to go through just yet.

[jotoha2] 04/3/2010 08:17

So looks like 2011 is going to be the pivotal moment for this little baby, expect it to rise significantly as we get closer to that point, time to start buying big time.

[roundyg] 26/2/2010 08:03

Not a yankee in sight there!

[nod] 26/2/2010 02:09

Man City then ;)

[rconst2] 24/2/2010 17:21

I said small

[novicetrade68] 24/2/2010 15:31

Man United ?

[rconst2] 24/2/2010 15:27

I think the lemming season is not too far away, .5p is on the card. To many gravy train passengers for my liking. Name me one UK small concern that has prospered with a yankee taking over the reins.

[nod] 24/2/2010 09:27

LMT has taken a bashing this month. Although it has raised cash to see it through another year and more, it's a really long-term investment. Today, there's not many peeps looking for 3 year investments in small companies.

[nod] 03/2/2010 18:57

The market valuation of LMT is now £22.8 million

[nod] 01/2/2010 21:05

London, UK, 1 February 2010 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company, is pleased to announce that at the General Meeting of the Company held today all of the resolutions were duly passed by shareholders, including Resolution 1 which was passed by a poll with 300,541,363 in favour and 10,000 against.

Application has been made for the 1,333,390,207 placing, subscription and offer shares of 1p each to be admitted to trading on AIM. It is expected that admission of these shares ("Admission") will become effective and dealings will commence on AIM at 08.00 am on 2 February 2010. Following Admission, Invesco Asset Management Limited will have an interest in 955,179,756 shares of 1p each representing approximately 43.92 per cent. of the enlarged issued share capital of the Company.

[nod] 29/1/2010 21:48

I didn't subscribe to the new shares... I tried but subscription through TD Waterhouse online would not work. I tried buying online many times over the week and received a message to phone TDW. This was easier said than done - in part because I'm overseas. I tried phoning several times but none of the automated options seemed appropriate and I was placed in a long queue each time. I never got to speak to a human.

I don't know why buying online would not work. It should be easy.

If other private investors have similar difficulties it would not help the take up. Just as well LMT went to institutions.

[webshares] 29/1/2010 16:47

i'm just in here for a punt i don't have a massive holding but we'll see what happens on 2nd feb onwards

[jotoha2] 29/1/2010 15:02

Rightly so , most people are happy to wait for news of developments , far better to pay a bit more when the positive news starts to come in .

[peterboroughmatt] 29/1/2010 09:51

not a very good take up then

[nod] 29/1/2010 09:08

On 13 January 2010, the Company announced a fund raising that included an offer to qualifying participants of up to 196,960,873 new ordinary shares of 1 pence each of the Company ("Shares") at a price of 1 pence per Share (the "Offer").

The Company is pleased to announce that, at the close of the Offer, qualifying participants had applied for 31,370,800 new ordinary shares of 1p each at a price of 1p per share raising £313,708.

The Offer was in addition to the placing and subscription, also announced on 13 January 2010, which conditionally raised £13 million ("Placing and Subscription").

The Offer, together with the Placing and Subscription, are subject to the approval of shareholders of the Company at a general meeting to be held at 11.00 a.m on 1 February 2010.

Subject to such approval, it is expected that dealings in the 1,333,390,207 Shares issued pursuant to the Offer and the Placing and Subscription will commence on AIM market of the London Stock Exchange on 2 February 2010.

[webshares] 28/1/2010 21:09

quick poll to see how many people subscribed to the share offer. i know we find out in a few days but was just wondering cheers

1. Me